Head-to-head · Cost-Efficiency Index
Goldspan Health vs NuuVim
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Goldspan Health
Shoppers who want a sublingual route priced openly beside the injection and who will count 13 charges a year rather than 12.
Visit Goldspan HealthNuuVim
Cost-first shoppers who want low-cost compounded GLP-1s (injection or oral), flat all-dose pricing.
Visit NuuVimThe verdict
Goldspan Health takes it, leading the Cost-Efficiency Index 71 to 70. Goldspan Health sells compounded semaglutide at $229 and tirzepatide at $299 every 28 days, with daily sublingual and low-dose versions of both at lower prices, through a storefront operated by a different company. NuuVim still earns a C — Cost-first shoppers who want low-cost compounded GLP-1s (injection or oral), flat all-dose pricing.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Goldspan Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Goldspan Health | NuuVim |
|---|---|---|
| Cost-Efficiency Index | 71/100 | 70/100 |
| Semaglutide / mo | $229 every 28 days month-to-month (13 charges a year, not 12) | $79/mo (all doses, 3-mo plan, new patients only, compounded) |
| Tirzepatide / mo | $299 every 28 days month-to-month (13 charges a year, not 12) | $133/mo (all doses, 3-mo plan, new patients only, compounded) |
| Semaglutide / yr (modeled) | $2,748 | $948 |
| Tirzepatide / yr (modeled) | $3,588 | $1,596 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | Yes | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #84 | #88 |
Goldspan Health
71/100Where the value is
- Prices ten separate GLP-1 products openly — injection and sublingual, standard and low dose, with a B12 or a glycine base — before any account
- Each plan card itemizes what the figure buys: the clinician evaluation, the medication, injection supplies, two-day shipping and clinical-team access
- States the billing cycle honestly on the plan card and the order timeline as 28 days and four weeks
The tradeoffs
- The hero prints "/month" over a plan billed every 28 days, which is 13 charges a year rather than 12
- "Pause, delay, or cancel at any time" sits against a refund policy reading "all sales are final" and storefront terms saying an order cannot be canceled once placed
NuuVim
70/100Where the value is
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
The tradeoffs
- There is no month-to-month plan: every rate is billed as one three-month payment
- The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.